Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476783 · ClinicalTrials.gov registry record · Phase 2
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
A Phase 2 study, sponsored by TrueBinding.
- Terminated
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05476783: Clinical Trial Phase 2 study, sponsored by TrueBinding.
NCT05476783 is a Phase 2 study that was terminated before completion, run by TrueBinding. The registered enrollment target is 119 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05476783, a Phase 2 study, was terminated before completion, sponsored by TrueBinding.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.
Primary Outcome
Summary for Number of Participants with Adverse Events and Serious Adverse Events
Interventions
- DRUG TB006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Why NCT05476783 stopped before completion
NCT05476783 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 1 intervention - of which TB006 is the first listed.
NCT05476783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05476783 about?
NCT05476783 is a clinical study titled "A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease". This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tol...
What is the current status of trial NCT05476783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2022-09-15. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05476783?
The interventions under investigation include: TB006 (DRUG).
Who is sponsoring clinical trial NCT05476783?
This trial is sponsored by TrueBinding, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05476783's enrollment target sits among peer trials
119 618th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI